Form 4: BridgeBio Pharma Director Acquires Stock Options

Director Ali J. Satvat acquires stock options in BridgeBio Pharma, Inc.

Summary

• On June 21, 2024, Ali J. Satvat, a director of BridgeBio Pharma, Inc., acquired 26,014 stock options.
• The exercise price of the stock options is $27.36.
• The options vest in three equal annual installments starting June 21, 2024, and will be fully vested by June 21, 2027, contingent upon continued service on the board.
• The expiration date for the options is June 20, 2034.
• Following the transaction, Satvat directly owns 26,014 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The stock options vest over a three-year period, incentivizing the director to contribute to the company's long-term success.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it indicates confidence from a director.

Key Dates